New clinical study to test promising diabetes drug in people with MND

Could a diabetes drug be used for Motor Neurone Disease?

A diabetes drug could one day be used to treat neurodegenerative diseases like Motor Neurone Disease (MND), Alzheimer's and Parkinson's.

Researchers at Lancaster University in the UK are to conduct a clinical trial of the diabetes drug Liraglutide, giving it to patients with MND to see whether they improve or not.

MND is a progressive degenerative disorder of motor neurones that leads to muscle weakness and death.

Because neurodegenerative diseases are a "family" of diseases, if a new treatment can be found for one, it may be useful for others too.

The study is led by Professor Hedley Emsley, Consultant Neurologist, with Professor Christian Hölscher from Lancaster University, who previously discovered that Liraglutide can help patients with Alzheimer's.

Professor Holscher said: "This new trial is testing a very promising drug in people with MND, a dreadful condition for which there is no cure. We hope that this drug will make a difference."

There is increasing interest in the idea that drugs licensed for one disease may have some use in a different area.

Professor Emsley said: "Repurposing drugs in this way might lead to treatments for devastating disorders such as MND. Effective treatments for MND are sadly lacking."

There is also the advantage in that an existing drug overcomes the time and cost of drug development which may take up to a decade.

In treating diabetes, Liraglutide and related drugs control the release of insulin by binding to specific protein binding sites in the pancreas.

These cells are also found in cells in the brain where they appear to play a role in maintaining the metabolic health of neurones.

Research showing that activation of these receptor sites with drugs can protect neurones from damage.

Source: http://www.lancaster.ac.uk/news/articles/2017/could-a-diabetes-drug-be-used-for-motor-neurone-disease-/

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study links obesity and diabetes to higher recurrence rates in liver cancer